Member Info for Parpaing

davie46 is right. I bought my shares at 16p in 2010 and have averaged down to 6p. i am reluctant to buy more considering the AIM market is just a casino. TRP had a 'glow in the dark' ramp and i lost 5 grand there. So I don't dance around when I see a 'sure thing' on AIM. for all I know this major story is like all the other BPC stories, fictional pirates black gold. I'm just hoping I get my money back lost on AIM via BPC, and the sum of 20p per BPC share will do it.

Halifax will charge you a 25GBP minimum. My bank will charge me 50 GBP, which it will cost you to lose all your money. This company needs investigating for mismanagement of investor money, forensic auditing to check that money has been spent in their 'glow in the dark' dealings. for all we know, the BOD has just been paying themselves for doing nothing. Flying around Africa using first class seats? This BOD has embarrassed the AIM market with 'legalized' thieving.

So my 5 grand spent 10 years ago, reduced to 480 shares and now reduced to 1 share at 1.6p is theft. The BOD should not profit in this way. Time for AIM to investigate the BOD and a forensic audit.

I've been in for ten years and bought at 22p, averaged down to 5p. Simon potter has 5 million shares and as this job is likely to be his last, he will need a good pension.BPC has been in the Bahamas for ten years, working with this project and the Bahamas Government. A lot of people will be looking forward to their rewards, hence the SP will, in my view, reach the 87p party and make my pension. At the very least, I hope that BPC will recover all my losses on other AIM shares, like the less than nice bank RBS.

Could also be BP or Exxonmobil. ExxonMobil�s activities in the Caribbean and Central America encompass the Bahamas, Barbados, Bermuda, the Dominican Republic, the Cayman Islands, Guadeloupe, Guatemala and Martinique, with Esso offices located in each country. Exxon is leading a group of companies developing 6.6-million-acres in Guyana�s waters that could make the country one of Latin America�s largest oil producers within a decade. That discovery has spurred interest in neighboring Suriname, while the government in the Bahamas is also opening offshore areas for exploration. See: https://www.rigzone.com/news/wire/dominican_republic_to_join_caribbean_energy_exploration_rush-05-mar-2018-153764-article/

Sorry, just bought at 2.9675

Just bought 37k at .2965 and its showing as a sell.

that this stock isn't being traded more often.

So what is the amended annual report for? Just to explain the exaggerated salaries of the board?

With all the dilution the SP needs to be �9.55 to break even. At the moment, it will cost be to sell the shares in this dreadful company.

but what about a nice dividend when the company makes a good profit?

That the SP hasn't shot up. Obviously not many people know about this share. It's a solid buy with no downsides now that the government and companies are getting involved. A solid and strong buy IMO.

free floating shares in BIOM will mean that the SP will double or treble very soon.

Hi Flapping, Many thanks for the articles - all very interesting. If you go to the AGM, ask the board if they have enough raw products to meet the demand in bags, coffee cups, straws, cotton buds etc. because this market is going to increase exponentially now that governments are getting involved.

Thanks for the news Flapping, IMO this SP is going to double towards the last quarter of 2018.

Have you got any info on SynBio's clinical trial protocol number, because I cannot find Synbio in any trial in Russia. I have found a Pharmasyntez clinical trial which is Virexxa (XBIO -101) See: https://clinicaltrials.gov/ct2/show/NCT02064725 . The clinical study sponsor is Kevelt AS. The study ends in July 2018. Synbio's website doesn't work.

Well done to the boom staff. This company is going to increase their turnover dramatically over the next three years.

The Baxalta (now part of Shire) study results for PolyXen were submitted to clinicaltrials.gov on January 14, 2018 but are not yet publicly available. The study completion date was January 17 2017. The estimated primary completion date for XBIO -101 (Virexxa) was January 2018 and the estimated study completion date is July 2018. No results have been posted but Kevelt the study sponsor, and Pharmsyntez has this information so XBIO should have it too. However, the Virexxa drug will be manufactured in Estonia, but no mention of XBIO getting a slice of the action. In 2015 Kevelt sold the rights of Virexxa to US stock company Xenetic Biosciences Inc. (see: http://www.jforcs.com/wp-content/uploads/2016/08/Therapeutics-2-Virexxa.pdf ). Virexxa has orphan drug status in the US and that was in 2016. Is the company still waiting for the study 2 resuts? The product pipeline is reduced and I'm surprised that the company is still afloat, considering that there is no news at all.

27 March 2018 Preliminary Results, Report & Accounts, Notice of AGM.

Jeremy Asher, Chairman & CEO, commented: �Commencing the ESIA process now is important to enable Tower to be in a position to commence drilling in the second half of 2018.� Asher also added: �This represents a further step towards our goal of reaching oil production at Thali as soon as possible.� Tower Resources holds a 100% interest in the shallow water Thali (formerly known as �Dissoni�) Production Sharing Contract (PSC), in the Rio del Rey basin, offshore Cameroon. Tower was awarded the PSC on September 15, 2015, for an Initial Exploration Period of three years. The Thali PSC covers an area of 119.2 km�, with water depths ranging from 8 to 48 meters, and lies in the prolific Rio del Rey basin, in the eastern part of the Niger Delta. https://www.offshoreenergytoday.com/tower-resources-awards-esia-contract-ahead-of-drilling-campaign-on-thali-license/